Navigation Links
Spherix Announces 2008 Financial Results
Date:3/30/2009

BETHESDA, Md., March 30 /PRNewswire-FirstCall/ -- Spherix Incorporated (Nasdaq: SPEX), an innovator in biotechnology and a provider of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies, today reported results for the year ended December 31, 2008.

Recent Company Highlights

  • Biospherics
    • Naturlose(R) Phase 3 clinical trial investigating efficacy as a treatment for Type 2 diabetes continues on schedule; completion expected in mid-2010
    • Interim data results expected in third quarter of 2009
    • Completion of the related Phase 2 Dose Range trial expected in 2009
    • Peer-reviewed publication of new results from animal studies

  • Spherix Consulting
    • Revenue from health sciences consulting services has grown every quarter since its start in July 2007
    • Additional consulting staff hired to handle increased demand

"The next few months will be an exciting time for Spherix and its shareholders," stated Dr. Claire L. Kruger, CEO of Spherix. "The Company anticipates sharing interim data in the fall from its ongoing Phase 3 clinical trial investigating the efficacy of Naturlose as a novel treatment for Type 2 diabetes. I am pleased to report that Spherix will be holding its first earnings webcast on April 2, during which we will provide our shareholders and other interested parties with additional information and updates on both the Biospherics and Spherix Consulting subsidiaries."

Financial Results for the Year Ended 2008


'/>"/>

SOURCE Spherix Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Spherix Shareholders Support Companys Focus on Naturlose, Biotechnology
2. Spherix Reports 3rd Quarter Earnings
3. Spherix Reports 2007 Financial Results
4. Spherix Hires Key Employees
5. Spherix Holds Annual Shareholders Meeting
6. Spherix Reports 1st Quarter Earnings
7. Spherix Receives NASDAQ Bid Price Deficiency Letter
8. Spherix Receives Nasdaq Letter Extending Minimum Bid Price Compliance Period
9. Spherix Transfers Stock Listing to Nasdaq Capital Market
10. Spherix Reports 3rd Quarter Earnings
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... The Microcompetition with Foreign DNA theory explains ... these latent viruses is the Epstein Barr Virus (EBV), and ... (RA) is a chronic inflammatory disease that destroys the body’s ... RA patients have high concentrations of EBV DNA in their ...
(Date:1/15/2014)... Scottsdale, Arizona (PRWEB) January 15, 2014 ... growth for Scottsdale’s Brain State Technologies®. They saw continued ... University Medical Center who were awarded a $1 million ... papers published in “Brain and Behavior” a peer reviewed ...
(Date:1/15/2014)... 2014 AudioNotch is the internet's leading ... the treatment of tinnitus. Patients listen to sound therapy ... a period of weeks to months, their tinnitus volume decreases. ... forms: Notched Music and Notched White Noise. Now, AudioNotch is ...
(Date:1/14/2014)... 2014 Date: Friday, April 11, 2014 , ... Club, 1360 Almshouse Road, Warrington, Pa. , Details: ... dedicated to finding a cure for hepatitis B and improving ... its annual Crystal Ball on Friday, April 11 at Warrington ...
Breaking Biology Technology:Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 2Study: Rheumatoid Arthritis (RA) Patients Have EBV; The CBCD Says this is Consistent with Microcompetition 3Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 2Dynamic Innovative Technology Showcased at Scottsdale Company’s Open House 3Hepatitis B Foundation to Host Annual Crystal Ball Gala 2
... CellCyte Genetics,Corporation (CellCyte) (OTC Bulletin Board: CCYG) ... investment and financial advice and,services. CellCyte seeks to ... technologies and will work with InCap to initiate ... of,CellCyte,s cell expander and stem cell delivery technologies., ...
... China, July 9 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE:,WX), ... development outsourcing company with operations in China and ... D. Bryans, Vice President,and General Manager of WuXi ... of WuXi PharmaTech (Cayman) Inc., has been invited,to ...
... organic light-emitting diodes, require a transparent conductive layer with ... electron holes into an organic layer to produce more ... the International Conference on Science and Technology of Synthetic ... the injection efficiency. A balanced injection of positive and ...
Cached Biology Technology:CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 2CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 3CellCyte Genetics Retains InCap Group to Advise on Business Strategy and Financing 4WuXi AppTec VP and GM Invited to Join the AAMI Standards Board 2WuXi AppTec VP and GM Invited to Join the AAMI Standards Board 3Research helps understand factors that influence efficiency of organic-based devices 2Research helps understand factors that influence efficiency of organic-based devices 3
(Date:7/9/2014)... crucial piece of the puzzle behind nature,s ability ... could help advance the development of artificial photosynthesis ... provided by an international collaboration of scientists led ... (Berkeley Lab) and the SLAC National Accelerator Laboratory. ... Source (LCLS), the world,s most powerful x-ray laser, ...
(Date:7/9/2014)... (TCGA) Research Network have identified novel mutations in ... most common subtype of lung cancer. Knowledge of ... possible therapeutic targets for this disease and potentially ... mutations because many potent cancer drugs that target ... funded and managed by the National Cancer Institute ...
(Date:7/9/2014)... Ill. With over 100 diseases that can attack ... top of the most wanted list? University of Illinois ... that more research is needed on the fungus that ... with cool, damp growing conditions but Macrophomina phaseolina ... and dry drought conditions. , "As the climate continues ...
Breaking Biology News(10 mins):Postcards from the photosynthetic edge 2Postcards from the photosynthetic edge 3Study identifies novel genomic changes in the most common type of lung cancer 2Study identifies novel genomic changes in the most common type of lung cancer 3Climate change provides good growing conditions for charcoal rot in soybeans 2Climate change provides good growing conditions for charcoal rot in soybeans 3
... This press release is available in German . ... the most fascinating species of the Galapagos archipelago, treks ... the Max Planck Institute for Ornithology in Radolfzell, together ... and modern 3D acceleration measurements to find out that ...
... becoming cannier about turning down the thermostat to save our ... when we get to work? A new 1.3m project, ... to look at people,s attitudes to energy consumption in the ... reducing their organisation,s carbon footprint. Drawing on technical expertise ...
... Elsevier, a world-leading provider of scientific, technical and medical ... new, international, open access journal, Case Studies in ... in Engineering Failure Analysis provides a forum for ... in Engineering Failure Analysis and will form an ...
Cached Biology News:Galapagos tortoises are a migrating species 2Galapagos tortoises are a migrating species 3An energy conscious workforce: New research looks at how to encourage staff to go green 2Elsevier launches new open access journal -- 'Case Studies in Engineering Failure Analysis' 2